ACADIA Pharmaceuticals Inc. Investors: Please contact the Portnoy Law Firm to recover your losses
Investors can contact the law firm at no cost to learn more about recovering their losses
LOS ANGELES, Feb. 22, 2024 (GLOBE NEWSWIRE) — The Portnoy Law Firm advises ACADIA Pharmaceuticals Inc. (“ACADIA” or the “Company”) (NASDAQ: ACAD) investors that the law firm has initiated an investigation on behalf of investors that lost money on their ACADIA stock. ACADIA investors are encouraged to contact the firm to discuss their legal rights.
Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses.
On February 15, 2024, Culper Research released a critical analysis suggesting that ACADIA’s much-awaited drug for treating Ret Syndrome, Daybue, launched in April 2023, has failed to meet expectations. According to Culper, the drug has disappointed patients, caregivers, physicians, and insurers alike, with the initiation of new patient treatments peaking last summer. They argue that Daybue will generate revenues significantly lower than initial projections, and its underperformance will further strain ACADIA’s financial resources. Following the release of this report, ACADIA’s stock value dropped by $0.38, a 1.49% decrease, ending the day at $25.18 per share.
Please visit our website to review more information and submit your transaction information.
The Portnoy Law Firm represents investors in pursuing claims caused by corporate wrongdoing. The Firm’s founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes.
Lesley F. Portnoy, Esq.
Admitted CA and NY Bar
[email protected]
310-692-8883
www.portnoylaw.com
Attorney Advertising
